Ocular Therapeutix Stock Total Debt
| OCUL Stock | USD 9.89 0.17 1.69% |
Ocular Therapeutix fundamentals help investors to digest information that contributes to Ocular Therapeutix's financial success or failures. It also enables traders to predict the movement of Ocular Stock. The fundamental analysis module provides a way to measure Ocular Therapeutix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocular Therapeutix stock.
The value of Total Debt To Capitalization is expected to slide to 0.28. Ocular | Total Debt |
Ocular Therapeutix Company Total Debt Analysis
Ocular Therapeutix's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Ocular Therapeutix Total Debt | 83.39 M |
Most of Ocular Therapeutix's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocular Therapeutix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ocular Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Ocular Therapeutix is extremely important. It helps to project a fair market value of Ocular Stock properly, considering its historical fundamentals such as Total Debt. Since Ocular Therapeutix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ocular Therapeutix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ocular Therapeutix's interrelated accounts and indicators.
Click cells to compare fundamentals
Ocular Total Debt Historical Pattern
Today, most investors in Ocular Therapeutix Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ocular Therapeutix's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Ocular Therapeutix total debt as a starting point in their analysis.
Ocular Therapeutix Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Ocular Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Ocular Therapeutix has a Total Debt of 83.39 M. This is 96.97% lower than that of the Pharmaceuticals sector and 74.32% lower than that of the Health Care industry. The total debt for all United States stocks is 98.43% higher than that of the company.
Ocular Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocular Therapeutix's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocular Therapeutix could also be used in its relative valuation, which is a method of valuing Ocular Therapeutix by comparing valuation metrics of similar companies.Ocular Therapeutix is currently under evaluation in total debt category among its peers.
Ocular Therapeutix Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ocular Therapeutix from analyzing Ocular Therapeutix's financial statements. These drivers represent accounts that assess Ocular Therapeutix's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ocular Therapeutix's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 178.8M | 1.3B | 532.5M | 216.0M | 356.0M | 238.3M | |
| Enterprise Value | 183.7M | 1.1B | 427.3M | 178.0M | 243.6M | 200.8M |
Ocular Therapeutix ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ocular Therapeutix's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ocular Therapeutix's managers, analysts, and investors.Environmental | Governance | Social |
Ocular Therapeutix Institutional Holders
Institutional Holdings refers to the ownership stake in Ocular Therapeutix that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ocular Therapeutix's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ocular Therapeutix's value.| Shares | State Street Corp | 2024-09-30 | 3.5 M | Perceptive Advisors Llc | 2024-09-30 | 3.3 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Assenagon Asset Management Sa | 2024-09-30 | 2.8 M | Deltec Asset Management Llc | 2024-09-30 | 2.6 M | Octagon Capital Advisors Lp | 2024-09-30 | 2.4 M | Braidwell Lp | 2024-09-30 | 2.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.6 M | Summer Road Llc | 2024-09-30 | 14.4 M | Vr Adviser, Llc | 2024-09-30 | 12.8 M |
Ocular Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.26) % | ||||
| Operating Margin | (2.65) % | ||||
| Current Valuation | 1.2 B | ||||
| Shares Outstanding | 157.22 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 91.07 % | ||||
| Number Of Shares Shorted | 10.78 M | ||||
| Price To Earning | (2.69) X | ||||
| Price To Book | 4.42 X | ||||
| Price To Sales | 25.89 X | ||||
| Revenue | 58.44 M | ||||
| Gross Profit | (6.51 M) | ||||
| EBITDA | (66.42 M) | ||||
| Net Income | (80.74 M) | ||||
| Cash And Equivalents | 134.54 M | ||||
| Cash Per Share | 1.75 X | ||||
| Total Debt | 83.39 M | ||||
| Debt To Equity | 0.90 % | ||||
| Current Ratio | 6.14 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (70.23 M) | ||||
| Short Ratio | 9.68 X | ||||
| Earnings Per Share | (1.29) X | ||||
| Target Price | 18.22 | ||||
| Number Of Employees | 267 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 1.58 B | ||||
| Total Asset | 252.06 M | ||||
| Retained Earnings | (697.58 M) | ||||
| Working Capital | 197.34 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 5.38 M | ||||
| Net Asset | 252.06 M |
About Ocular Therapeutix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocular Therapeutix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocular Therapeutix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocular Therapeutix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Ocular Therapeutix Piotroski F Score and Ocular Therapeutix Altman Z Score analysis. For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.29) | Revenue Per Share 0.529 | Quarterly Revenue Growth 0.083 | Return On Assets (0.22) | Return On Equity (0.73) |
The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.